Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.75.

Several research firms recently weighed in on KLRS. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Wedbush assumed coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They set an “outperform” rating and a $17.00 price target for the company. Citizens Jmp decreased their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, TD Cowen started coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They set a “buy” rating for the company.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics during the third quarter valued at $58,000. Bridgeway Capital Management LLC purchased a new stake in Kalaris Therapeutics during the 3rd quarter worth about $130,000. Woodline Partners LP acquired a new position in Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. Finally, WHI TRUST Co LLC acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $823,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $4.03 on Monday. The stock has a market capitalization of $95.95 million, a price-to-earnings ratio of -2.00 and a beta of 0.20. Kalaris Therapeutics has a 52 week low of $3.03 and a 52 week high of $11.88. The firm has a 50-day moving average price of $4.17 and a 200 day moving average price of $5.76.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. Equities research analysts expect that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.